febuxostat has been researched along with diacerein in 2 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (diacerein) | Trials (diacerein) | Recent Studies (post-2010) (diacerein) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 315 | 49 | 157 |
| Protein | Taxonomy | febuxostat (IC50) | diacerein (IC50) |
|---|---|---|---|
| 90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | 9.234 | |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | 9.234 | |
| Female germline-specific tumor suppressor gld-1 | Caenorhabditis elegans | 7.308 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 6.4 | |
| Transthyretin | Homo sapiens (human) | 5.4 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.7 | |
| N-acylethanolamine-hydrolyzing acid amidase | Homo sapiens (human) | 0.7 | |
| Monoglyceride lipase | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Hu, SX; Lei, XM; Shen, GF; Ye, C; Yu, F; Yu, YK; Zhang, ST | 1 |
1 trial(s) available for febuxostat and diacerein
| Article | Year |
|---|---|
Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout.
Topics: Adult; Anthraquinones; Anti-Inflammatory Agents; C-Reactive Protein; Case-Control Studies; Drug Therapy, Combination; Etoricoxib; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Interleukin-18; Interleukin-1beta; Male; Middle Aged; Prospective Studies; Pyridines; Sulfones; Treatment Outcome; Uric Acid | 2017 |
1 other study(ies) available for febuxostat and diacerein
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |